Table 1. Mean DAS28 score for each site as baseline, 6 month, and 12 month visits*
| F | C | A | D | G | E | H | B | p-value | |
|---|---|---|---|---|---|---|---|---|---|
| Number of patients at baseline | 58 | 85 | 92 | 121 | 143 | 157 | 224 | 255 | |
| Baseline DAS28, mean ±SD | 4.63±1.35 | 4.34±1.53 | 4.76±1.19 | 4.21±1.27 | 4.02±1.36 | 4.86±1.28 | 4.30±1.35 | 4.76±1.45 | 0.000 |
| 6 months DAS28, mean ± SD | 3.50±1.61 | 2.76±1.44 | 3.71±1.31 | 2.69±1.16 | 2.77±1.14 | 3.25±1.36 | 2.29±1.04 | 3.11±1.40 | 0.000 |
| 12 months DAS28, mean ± SD | 3.14±1.36 | 2.71±1.29 | 3.31±1.54 | 2.43±1.03 | 2.66±0.99 | 2.86±1.14 | 2.17±0.88 | 2.72±1.39 | 0.000 |
| Change in DAS28 from baseline to 6 months, mean ± SD | –1.12±1.57 | –1.63±1.80 | –1.09±1.34 | –1.56±1.48 | –1.17±1.33 | –1.79±1.68 | –2.09±1.72 | –1.82±1.70 | 0.000 |
. Two sites started with combination DMARDs more frequently (site B [largest] and G; p<0.000) and site H [2nd largest] parenteral MTX (20-25mg sc weekly) at initial visit more than other sites (p<0.000).